These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12077721)

  • 1. Pharmacogenomics in cardiovascular diseases.
    Mukherjee D; Topol EJ
    Prog Cardiovasc Dis; 2002; 44(6):479-98. PubMed ID: 12077721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.
    Terra SG; Johnson JA
    Am J Cardiovasc Drugs; 2002; 2(5):287-96. PubMed ID: 14727958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.
    Mango R; Vecchione L; Raso B; Borgiani P; Brunetti E; Mehta JL; Lauro R; Romeo F; Novelli G
    Expert Opin Pharmacother; 2005 Dec; 6(15):2565-76. PubMed ID: 16316297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacogenomics of cardiovascular pharmacology].
    Tanaka T; Oka T; Iwao H
    Nihon Yakurigaku Zasshi; 2006 Sep; 128(3):130-2. PubMed ID: 16971774
    [No Abstract]   [Full Text] [Related]  

  • 5. New collaborations make pharmacogenomics a SNP.
    Dawson E
    Mol Med Today; 1999 Jul; 5(7):280. PubMed ID: 10377514
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical applications of pharmacogenomics.
    Quiñones L; Roco Á; Cayún JP; Escalante P; Miranda C; Varela N; Meneses F; Gallegos B; Zaruma-Torres F; Lares-Asseff I
    Rev Med Chil; 2017 Apr; 145(4):483-500. PubMed ID: 28748996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.
    Della-Morte D; Palmirotta R; Rehni AK; Pastore D; Capuani B; Pacifici F; De Marchis ML; Dave KR; Bellia A; Fogliame G; Ferroni P; Donadel G; Cacciatore F; Abete P; Dong C; Pileggi A; Roselli M; Ricordi C; Sbraccia P; Guadagni F; Rundek T; Lauro D
    Pharmacogenomics; 2014 Dec; 15(16):2063-82. PubMed ID: 25521362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.
    Dubé MP; de Denus S; Tardif JC
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):59-64. PubMed ID: 26768480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic implications of the eNOS polymorphisms for cardiovascular action drugs.
    Silva PS; Lacchini R; Gomes Vde A; Tanus-Santos JE
    Arq Bras Cardiol; 2011 Feb; 96(2):e27-34. PubMed ID: 21445464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice.
    Shahabi P; Dubé MP
    Int J Cardiol; 2015 Apr; 184():772-795. PubMed ID: 25838112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics and the potential for personalized therapeutics in cardiovascular disease.
    Kayser SR
    Prog Cardiovasc Nurs; 2007; 22(2):104-7. PubMed ID: 17541322
    [No Abstract]   [Full Text] [Related]  

  • 12. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
    Verschuren JJ; Trompet S; Wessels JA; Guchelaar HJ; de Maat MP; Simoons ML; Jukema JW
    Eur Heart J; 2012 Jan; 33(2):165-75. PubMed ID: 21804109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics: unlocking the human genome for better drug therapy.
    McLeod HL; Evans WE
    Annu Rev Pharmacol Toxicol; 2001; 41():101-21. PubMed ID: 11264452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular pharmacogenomics.
    Roden DM
    Circulation; 2003 Dec; 108(25):3071-4. PubMed ID: 14691022
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacogenomics: the inherited basis for interindividual differences in drug response.
    Evans WE; Johnson JA
    Annu Rev Genomics Hum Genet; 2001; 2():9-39. PubMed ID: 11701642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular pharmacogenomics.
    Johnson JA; Cavallari LH
    Exp Physiol; 2005 May; 90(3):283-9. PubMed ID: 15778411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease.
    Winkelmann BR; März W; Boehm BO; Zotz R; Hager J; Hellstern P; Senges J;
    Pharmacogenomics; 2001 Feb; 2(1 Suppl 1):S1-73. PubMed ID: 11258203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases.
    Zaiou M; Benachour H; Marteau JB; Visvikis-Siest S; Siest G
    Curr Pharm Des; 2009; 15(27):3193-206. PubMed ID: 19754391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacogenomics and pharmacoproteomics: a strategy for cardio-vascular drugs].
    Siest G; Marteau JB; Maumus S; Berrahmoune H; Jeannesson E; Samara A; Batt AM; Visvikis-Siest S
    Ann Pharm Fr; 2007 May; 65(3):203-10. PubMed ID: 17489077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management.
    Humma LM; Terra SG
    Am J Health Syst Pharm; 2002 Jul; 59(13):1241-52. PubMed ID: 12116890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.